|Security||LJPC / La Jolla Pharmaceutical Co. (503459604)|
|Latest Market Date||2018-09-21|
Short Interest and Volume
LJPC / La Jolla Pharmaceutical Co. short volume is shown in the following chart. Short Volume is a data set that can be used to understand investor sentiment. When an investor makes a short sale, they do so with the belief that a security will decline in price. If the short sale volume increases as a percentage of the total volume, then that suggests a bearish (negative) sentiment by the market. If short sale volume decreases as a percentage of total volume, then that suggests a bullish (positive) sentiment.
- Short Volume
- Total number of short shares traded on the major US markets each day
- Short Percent
- Total number of short shares traded divided by the total shares traded each day
- Short Interest
- Total number of open short positions of a security, divided by the total float (not shown)
- Short Squeeze
- When a company with a high degree of short interest increases in price, which forces short sellers to "cover" their short interest buy buying actual shares, which in turn drives the price up even further.
Note that Short Percent on this page is not the same as Short Interest. Short Interest is a measure of the number of open short positions of a security, divided by the total float. Short Percent is the daily short volume divided by the total volume. Short Interest is not available for this security at this time.
|Market Date||Total Volume||Short Volume||Short Percent|
Related News Stories
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (298-9)
Biotechnology stocks have a reputation for being some of the most speculative, most volatile stocks out there. Investors and would-be investors have to stay alert to avoid getting burned. One encouraging sign in any company is when insiders put their money where their mouth is and buy shares. Lately, some insiders at biotech companies have been doing just that, sometimes taking advantage of share price moves (not to mention buy windows opening up) in the wake of the release of quarterly reports. (24-12)
La Jolla Pharmaceutical Co (NASDAQ:LJPC) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET
Galectin Therapeutics (NASDAQ:GALT) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (NYSEARCA:IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise of a key departing officer continued to weigh on the price. Based on the recent Form 4 Filings, the selling pressure has abated because the officers have simply run out of options to sell. (24-2)
Biotech stocks represent a peculiar conundrum. On one hand, they are scientifically the most exciting investment sector. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. But the industry is heavily marked with failures and agonizing disappointments. (7-1)
as of ET